A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- Conditions
- Fallopian Tube CancerPrimary Peritoneal CarcinomaClear Cell CarcinomaOvarian Cancer
- Interventions
- Drug: 6 cycles chemotherapyDrug: 3 cycles chemotherapy instead of 6 cycles chemotherapy
- Registration Number
- NCT05460000
- Brief Summary
Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib.
- Detailed Description
This is a multicenter, randomized, open label study including patients with advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking.
The main scope of the trial is to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib.
Patients will be randomized 1:1 to receive either 3 cycles carboplatin + paclitaxel maintenance therapy with niraparib (Arm A) or 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (Arm B). Randomization will be performed according to the results of the NGS analysis and stratified either to BRCAm independent of LOH or LOHhigh/ BRCAwt, FIGO stage III vs. IV, and countries. In both of the arms, tumor assessments (CT or MRI) will be performed 9-12 weeks after the start of therapy (after 3rd cycle of chemotherapy), after another 9-12 weeks (during maintenance therapy in Arm A and after the 6th cycle of chemotherapy in Arm B) and every 6 months thereafter. The tumor marker CA-125 will be assessed every 12 weeks in both arms.
During chemotherapy treatment, clinical visits (blood cell counts, detection of toxicity) occur at least every 3 weeks (depending on the chemotherapy regimen). Serum pregnancy tests for WOCBP occur at least every 4 weeks. During maintenance therapy with niraparib, clinical visits (blood cell counts, detection of toxicity) occur every 4 weeks for the first 11 months and every 12 weeks thereafter. Serum pregnancy tests for WOCBP occur at least every 4 weeks. Complete physical examinations will take place every 12 weeks. Safety will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs).
About 60 sites in 6 European countries will participate in this study to recruit 640 patients in 36 months.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 640
-
Written informed consent and obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
-
Female patient, age ≥ 18 years.
-
FIGO Stage III-IV high-grade ovarian cancer (all histological types, except mucinous histology)
-
Complete primary debulked patients (without any macroscopic residuals), confirmed by CT-Scan postoperatively.
-
Patients must have formalin-fixed, paraffin-embedded tumor samples available from the primary cancer for central NGS analysis and must be HRDpositive defined as BRCAmut independent of NOGGO GIS Score OR NOGGO GIS Score >83 independent of BRCA status, based on these results.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
-
Patients must be able to take oral medications.
-
Synchronous and secondary malignancies are allowed if the prognosis of the ovarian cancer is not affected. The investigator must contact the medical monitoring team before enrolling the patient in the clinical trial.
-
Patients must have normal organ and bone marrow function:
- Hemoglobin ≥ 10.0 g/dL independent of transfusion ≤ 14 days prior to screening hemoglobin assessment
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); < 2 × ULN if hyperbilirubinemia is due to Gilbert's syndrome
- Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2,5 x ULN
- Serum creatinine ≤ 1.5 x institutional ULN and creatinine clearance > 30 mL/min.
-
Postmenopausal or evidence of non-childbearing status for women of childbearing potential prior to the first dose of study treatment. Female patients of childbearing potential must have a negative serum pregnancy test result ≤3 days prior to administration of the first dose of study treatment.
Patients are considered to be of childbearing potential unless 1 of the following applies:
- Considered to be permanently sterile. Permanent sterilization includes hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy; or
- Is postmenopausal, defined as no menses for at least 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level consistently in the postmenopausal range (30 mIU/mL or higher) may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to confirm a postmenopausal state.
Female patients of reproductive potential must practice highly effective methods (failure rate < 1% per year) of contraception with their partners, if of reproductive potential, during treatment and for 6 months following the last dose of chemotherapy or the last dose of niraparib, whichever occurs later, or longer if requested by local authorities. Highly effective contraception includes: Ongoing use of progesterone only injectable or implantable contraceptives; Placement of an intrauterine device (IUD) or intrauterine system (IUS); Bilateral tubal occlusion; Sexual abstinence as defined as complete or true abstinence, acceptable only when it is the usual and preferred lifestyle of the patient; periodic abstinence (e.g., calendar, symptothermal, post-ovulation methods) is not acceptable; or Sterilization of the male partner, with appropriate post-vasectomy documentation of absence of sperm in ejaculate.
-
Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e., germ cell tumors) and Ovarian tumors of low malignant potential (e.g., borderline tumors), or mucinous carcinoma of the ovary.
-
Low-grade ovarian, fallopian tube or peritoneal cancer.
-
Has known hypersensitivity to any of the study drugs or any of the excipients of any of the study drugs.
-
Has known hypersensitivity to platin-containing compounds other than carboplatin.
-
Patients posttransplant, including previous allogeneic bone marrow transplant.
-
Has undergone interval debulking of the tumor.
-
Has received any anti-cancer therapy for ovarian cancer other than primary surgery.
-
Administration of other simultaneous chemotherapy drugs, any other anti-cancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroidal antiemetics).
-
Has received prior treatment with a PARP inhibitor or has participated in a trial where any treatment arm included the administration of a PARP inhibitor.
-
Bevacizumab is planned to be given together with first line chemotherapy or as maintenance.
-
Clinically significant cardiovascular disease:
- Cerebrovascular accident or myocardial infarction or unstable angina ≤6 months before start of study treatment
- Severe cardiac arrhythmia (recent event or active or uncontrolled)
- New York Heart Association grade ≥2 congestive heart failure
- Uncontrolled hypertension (defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy or posterior reversible encephalopathy syndrome
- History of stroke or transient ischemic attack ≤6 months before start of study treatment
- Coronary/peripheral artery bypass graft ≤6 months before start of study treatment
- Deep vein thrombosis or thromboembolic events ≤1 month before start of study treatment
-
History or evidence of brain metastases or spinal cord compression.
-
Known history of MDS or a pre-treatment cytogenetic testing result at risk for a diagnosis of MDS/AML.
-
Current, clinically relevant bowel obstruction at the time of randomization.
-
Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
-
Pregnant or lactating women, women of child-bearing potential who do not agree to the usage of highly effective contraception methods (see inclusion criteria) starting with the screening visit through at least 6 months after the last dose of chemotherapy treatment or through at least 1 month after the last dose of niraparib, whichever occurs later.
-
Participation in another clinical study with an investigational product immediately prior to randomization. Earliest time point for randomization is after the time required for the investigational product to undergo 5 half-lives has passed.
-
Has a known history of Human Immunodeficiency Virus (HIV) infection (known HIV1/HIV2 antibodies positive) or acquired immunodeficiency syndrome (AIDS) related illness.
-
Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] has been detected) infection.
-
Has active infection with SARS-CoV-2 (antigen test).
-
Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of chemotherapy treatment and while and 28 days after the last dose of trial treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Administration of inactivated vaccines is allowed.
-
Patient has contraindications listed in the most recent SmPC.
-
Patient who might be dependent on the sponsor, CRO, site or the investigator.
-
In Germany: Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40a S. 1 Nr. 2 AMG.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm B (6 cycles of chemotherapy + maintenance therapy with niraparib) 6 cycles chemotherapy 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria. Arm A (3 cycles of chemotherapy + maintenance therapy with niraparib) 3 cycles chemotherapy instead of 6 cycles chemotherapy 3 cycles carboplatin + paclitaxel maintenance therapy with niraparib (starting dose 200 mg QD or 300 mg QD); maintenance continues until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria.
- Primary Outcome Measures
Name Time Method RFS 8 years Recurrence free survival, defined as time from treatment randomization to the earliest date of assessment of first relapse or death by any cause
- Secondary Outcome Measures
Name Time Method Safety Endpoints - safety of therapy (3 vs. 6 cycles of chemotherapy + niraparib maintenance therapy) according to CTCAE 5.0 criteria will be used as endpoint 8 years The safety objective is to characterize the safety and tolerability of 3 vs. 6 cycles of chemotherapy followed by maintenance therapy with niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking. The following safety parameters will be analyzed: adverse events and serious adverse events graded per NCI CTCAE, Version 5.0 criteria with time to onset/recovery, causality and outcome; changes in laboratory values, vital signs since baseline, treatment discontinuations and reason for discontinuation, death and cause of death etc. concomitant medications will be collected with time and reasons of use. These are routine safety parameters collected and analyzed in Phase II /III oncology trials.
Cost effectiveness 8 years The objective is to show that less cycles of chemotherapy are as efficient and at the same time less toxic. Additional cycles of chemotherapy significantly increase toxicity and therefore lead to an increase of costs regarding, e.g. in-patient treatment, concomitant medications to treat (S)AEs.
Overall survival (OS) 8 years time to event and rate at 3 and 5 years
Quality of Life (QoL) 1 8 years Patients are asked to answer the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30). Responses of questions 1-28 are based on a 4-point scale (1=not at all; 4=Very much), with a higher score indicating a high degree of symptomatology and must therefore be assessed negatively. Responses of questions 29 and 30 are based on a 7-point scale (1=Very poor; 7=Excellent), with a higher score indicating a better global health status.
Quality of Life 2 8 years Patients are asked to answer the EORTC QoL Questionnaire-Ovarian Cancer (QLQ-OV28). Responses are based on a 4-point scale (1=Not at all; 4=Very much), with a lower score indicating better symptoms.
TFST 8 years Time to first subsequent treatment
TWIST (Time Without Symptoms of disease progression or Toxicity of treatment) 8 years at baseline, 3, 6, and 12 months
PFS2 8 years Time from randomization until the date of second objective disease progression or death by any cause
Quality of Life/ Global health status 3 8 years Patients are asked to answer the short version of the SF-36 Health Survey (SF-12). The questionnaire contains a total of 12 questions with different response options. For questions 1, 8 and 12 there are 5 (1=excellent, 5=bad), for question 2-3 there are 3 (1=yes, very restricted, 3=no, not restricted at all) and for questions 9-11 there are 6 response options (1= always, 6 = never). Questions 4-7 can be answered with "Yes" or "No".
Trial Locations
- Locations (46)
Azienda USL IRCCS Di Reggio Emilia
🇮🇹Reggio Emilia, Italy
Cliniques Universitaires St. Luc
🇧🇪Brussels, Belgium
Jessa ziekenhuis
🇧🇪Hasselt, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
University Hospital Ostrava
🇨🇿Ostrava, Czechia
General University Hospital in Prague
🇨🇿Prague, Czechia
University Hospital Bulovka
🇨🇿Prague, Czechia
Klinikum Mittelbaden Baden-Baden Bühl
🇩🇪Baden-Baden, Germany
Uniklinikum Bonn
🇩🇪Bonn, Germany
Klinikum Lippe
🇩🇪Detmold, Germany
Florence-Nightingale-Krankenhaus Düsseldorf-Kaiserswerth
🇩🇪Düsseldorf, Germany
Universitätsklinikum Freiburg
🇩🇪Freiburg, Germany
Universitätsklinik Göttingen
🇩🇪Göttingen, Germany
Universitätsklinikum Hamburg-Eppendorf
🇩🇪Hamburg, Germany
SLK-Kliniken Heilbronn
🇩🇪Heilbronn, Germany
Universitätsklinikum Schleswig-Holstein Campus Kiel
🇩🇪Kiel, Germany
Universitätsklinikum Leipzig
🇩🇪Leipzig, Germany
Diakonie Klinikum Schwäbisch Hall
🇩🇪Schwäbisch Hall, Germany
Policlinico St. Orsola Malpighi
🇮🇹Bologna, Italy
ASST Spedali Civili di Brescia
🇮🇹Brescia, Italy
ASST Lecco - Ospedale A. Manzoni
🇮🇹Lecco, Italy
IRCCS Istituto nazionale dei Tumori
🇮🇹Milan, Italy
AOU Cagliari
🇮🇹Monserrato, Italy
Istituto Oncologico Veneto (IOV)
🇮🇹Padova, Italy
Azienda Ospedaliera Universitaria Pisana
🇮🇹Pisa, Italy
AO Ordine Mauriziano
🇮🇹Torino, Italy
H.U. Virgen de la Macarena
🇪🇸Sevilla, Spain
AOU Città della Salute e della Scienza di Torino - Ospedale Sant'Anna
🇮🇹Torino, Italy
Hospital Universitario Sant Joan de Reus
🇪🇸Tarragona, Spain
Universitätsklinik Innsbruck
🇦🇹Innsbruck, Austria
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum
🇩🇪Berlin, Germany
Hospital General Universitario Dr. Balmis
🇪🇸Alicante, Spain
Hospital Virgen de las Nieves
🇪🇸Granada, Spain
Hospital Universitario Lucus Augusti
🇪🇸Lugo, Spain
CIOCC Clara Campal
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocío
🇪🇸Sevilla, Spain
Hospital General Universitario de Valencia
🇪🇸Valencia, Spain
Hospital La Fe
🇪🇸Valencia, Spain
H. Althaia Manresa
🇪🇸Manresa, Spain
Universitätsklinikum Aachen
🇩🇪Aachen, Germany
DRK-Kliniken Berlin-Köpenick
🇩🇪Berlin, Germany
ZAHO Bonn Onkologische Praxis
🇩🇪Bonn, Germany
Universitätsklinikum Carl Gustav Carus
🇩🇪Dresden, Germany
Universitätsklinik der Johannes-Gutenberg Universität Mainz
🇩🇪Mainz, Germany
Christliches Klinikum Unna Mitte
🇩🇪Unna, Germany
Helios Dr. Horst Schmidt Kliniken Wiesbaden
🇩🇪Wiesbaden, Germany